Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | GSR | P00390 | 2/20 | 0.56 |
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL2129419 | 1.00 | ALOX15 (0.79) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL285915 | 1.00 | ALOX15 (0.79) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL27338522 | 0.94 | ALOX15 (0.70) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL3513355 | 0.93 | ALOX15 (0.68) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL14486023 | 0.93 | ALOX15 (0.68) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL3092424 | 0.93 | KMT2A (0.68) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL28647807 | 0.93 | KMT2A (0.68) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL6931889 | 0.93 | ALOX15 (0.68) | ALOX15BLMPMP22KMT2APTGS1 | |
| Glutamine SCHEMBL3092421 | 0.93 | KMT2A (0.68) | ALOX15BLMPMP22KMT2APTGS1 | |
| Succinamide SCHEMBL18261691 | 0.89 | PTGS1 (0.76) | ALOX15BLMPMP22KMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142947-A1 | Stabilized 3-Hydroxyflavan Compositions and Methods Therefor | MITSUI NORIN CO., LTD. (JP) | 2012-06-07 | — | — | US | claimed |
| US-8138359-B2 | Stabilized 3-hydroxyflavan compositions and methods therefor | MITSUI NORIN CO., LTD. (JP) | 2012-03-20 | — | — | US | claimed |
| US-20080300302-A1 | Stabilized 3-Hydroxyflavan Compositions and Methods Therefor | MITSUI NORIN CO., LTD. (JP) | 2008-12-04 | — | — | US | claimed |
| US-5972998-A | TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, NEPHRITIS, UVEITIS, THYROIDITIS, AND EARLY STAGE OF INSULIN DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, PSORIASIS AND INFLAMMATORY BOWEL DISEASE | HOECHST MARION ROUSSEL, INC. (US) | 1999-10-26 | — | — | US | claimed |
| WO-2024036373-A1 | BIOMARKERS AND USES THEREOF IN DIAGNOSIS AND TREATMENT OF NEUROLOGICAL POST ACUTE SEQUELAE OF COVID 19 (NPASC) | ANTISENSE THERAPEUTICS LTD (AU) | 2024-02-22 | — | — | WO | disclosed |
| EP-4253412-A2 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2023-10-04 | — | — | EP | disclosed |
| US-20230192857-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2023-06-22 | — | — | US | disclosed |
| US-11339220-B2 | Inhibition of cytokine-induced SH2 protein in NK cells | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH | 2022-05-24 | — | — | US | disclosed |
| US-20220025328-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2022-01-27 | — | — | US | disclosed |
| US-20220025048-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2022-01-27 | — | — | US | disclosed |
| CN-112972492-A | Inhibition of cytokine-induced SH2 protein in NK cells | 沃尔特及伊莱萨霍尔医学研究院 | 2021-06-18 | — | — | CN | disclosed |
| US-20210171636-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2021-06-10 | — | — | US | disclosed |
| US-5627044-A | Compositions and methods for protein structural determinations | MARTEK BIOSCIENCES CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| WO-1997014426-A1 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES MEDIATED BY ANTIGEN-PRESENTING CELLS | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0636183-A4 | COMPOSITIONS AND METHODS FOR PROTEIN STRUCTURAL DETERMINATIONS. | MARTEK BIOSCIENCES CORP (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996006629-A1 | HIGH-AFFINITY RESPONSE-SELECTIVE C-TERMINAL ANALOGS OF C5a ANAPHYLATOXIN | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1996-03-07 | — | — | WO | disclosed |
| EP-0636183-A1 | COMPOSITIONS AND METHODS FOR PROTEIN STRUCTURAL DETERMINATIONS | MARTEK BIOSCIENCES CORPORATION (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1994018339-A1 | COMPOSITIONS AND METHODS FOR PROTEIN STRUCTURAL DETERMINATIONS | MARTEK BIOSCIENCES CORPORATION (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0541716-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002240-A2 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192857-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | IL2, ILF2, CD74 | ALOX15 2607/4885BLM 4067/4885PMP22 4381/4885 |
| US-20120142947-A1 | Stabilized 3-Hydroxyflavan Compositions and Methods Therefor | GSTA1, GSTO1, GSTK1 | ALOX15 1155/4885BLM 1024/4885PMP22 4662/4885 |
| US-20220025048-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | IL2, ILF2, CD74 | ALOX15 2607/4885BLM 4067/4885PMP22 4381/4885 |
| US-11339220-B2 | Inhibition of cytokine-induced SH2 protein in NK cells | IL2, ILF2, LCP2 | ALOX15 2509/4885BLM 4210/4885PMP22 4389/4885 |
| US-20210171636-A1 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | IL2, ILF2, CD74 | ALOX15 2607/4885BLM 4067/4885PMP22 4381/4885 |
| US-20080300302-A1 | Stabilized 3-Hydroxyflavan Compositions and Methods Therefor | GSTA1, GSTO1, GSTK1 | ALOX15 1155/4885BLM 1024/4885PMP22 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.